These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

147 related items for PubMed ID: 1611094

  • 1. Unrelated donor bone marrow transplantation for correction of lethal congenital immunodeficiencies.
    Filipovich AH, Shapiro RS, Ramsay NK, Kim T, Blazar B, Kersey J, McGlave P.
    Blood; 1992 Jul 01; 80(1):270-6. PubMed ID: 1611094
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Unrelated donor marrow transplantation for congenital immunodeficiency and metabolic disease: an update of the experience of the Japan Marrow Donor Program.
    Sakata N, Kawa K, Kato K, Yabe H, Yabe M, Nagasawa M, Mugishima H, Kigasawa H, Tsuchida M, Akiyama Y, Morisima Y, Kodera Y, Kato S.
    Int J Hematol; 2004 Aug 01; 80(2):174-82. PubMed ID: 15481448
    [Abstract] [Full Text] [Related]

  • 4. Bone marrow transplantation from genetically HLA-nonidentical donors in children with fatal inherited disorders excluding severe combined immunodeficiencies: use of two monoclonal antibodies to prevent graft rejection.
    Jabado N, Le Deist F, Cant A, De Graeff-Meeders ER, Fasth A, Morgan G, Vellodi A, Hale G, Bujan W, Thomas C, Cavazzana-Calvo M, Wijdenes J, Fischer A.
    Pediatrics; 1996 Sep 01; 98(3 Pt 1):420-8. PubMed ID: 8784367
    [Abstract] [Full Text] [Related]

  • 5. Reduction of graft failure by a monoclonal antibody (anti-LFA-1 CD11a) after HLA nonidentical bone marrow transplantation in children with immunodeficiencies, osteopetrosis, and Fanconi's anemia: a European Group for Immunodeficiency/European Group for Bone Marrow Transplantation report.
    Fischer A, Friedrich W, Fasth A, Blanche S, Le Deist F, Girault D, Veber F, Vossen J, Lopez M, Griscelli C.
    Blood; 1991 Jan 15; 77(2):249-56. PubMed ID: 1985691
    [Abstract] [Full Text] [Related]

  • 6. CD6+ T cell depleted allogeneic bone marrow transplantation from genotypically HLA nonidentical related donors.
    Soiffer RJ, Mauch P, Fairclough D, Alyea E, Anderson K, Fisher D, Freedman A, Bartlett-Pandite L, Robertson M, Schlossman R, Gollob J, Marcus K, Murray C, Kuhlman C, Freeman A, Nadler L, Ritz J.
    Biol Blood Marrow Transplant; 1997 Apr 15; 3(1):11-7. PubMed ID: 9209736
    [Abstract] [Full Text] [Related]

  • 7. Umbilical cord blood transplantation in severe T-cell immunodeficiency disorders: two-year experience.
    Knutsen AP, Wall DA.
    J Clin Immunol; 2000 Nov 15; 20(6):466-76. PubMed ID: 11202237
    [Abstract] [Full Text] [Related]

  • 8. Monoclonal antibody T-cell-depleted HLA-haploidentical bone marrow transplantation for Wiskott-Aldrich syndrome.
    Rumelhart SL, Trigg ME, Horowitz SD, Hong R.
    Blood; 1990 Feb 15; 75(4):1031-5. PubMed ID: 2302455
    [Abstract] [Full Text] [Related]

  • 9. Impact of donor type on outcome of bone marrow transplantation for Wiskott-Aldrich syndrome: collaborative study of the International Bone Marrow Transplant Registry and the National Marrow Donor Program.
    Filipovich AH, Stone JV, Tomany SC, Ireland M, Kollman C, Pelz CJ, Casper JT, Cowan MJ, Edwards JR, Fasth A, Gale RP, Junker A, Kamani NR, Loechelt BJ, Pietryga DW, Ringdén O, Vowels M, Hegland J, Williams AV, Klein JP, Sobocinski KA, Rowlings PA, Horowitz MM.
    Blood; 2001 Mar 15; 97(6):1598-603. PubMed ID: 11238097
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Prevention of graft-versus-host disease with anti-CD5 ricin A chain immunotoxin after CD3-depleted HLA-nonidentical marrow transplantation in pediatric leukemia patients.
    Przepiorka D, Chan KW, Champlin RE, Culbert SJ, Petropoulos D, Ippoliti C, Khouri I, Huh YO, Vreisendorp H, Deisseroth AB.
    Bone Marrow Transplant; 1995 Dec 15; 16(6):737-41. PubMed ID: 8750262
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Combination graft-versus-host disease prophylaxis using immunotoxin (anti-CD5-RTA [Xomazyme-CD5]) plus methotrexate and cyclosporine or prednisone after unrelated donor marrow transplantation.
    Weisdorf D, Filipovich A, McGlave P, Ramsay N, Kersey J, Miller W, Blazar B.
    Bone Marrow Transplant; 1993 Nov 15; 12(5):531-6. PubMed ID: 8298565
    [Abstract] [Full Text] [Related]

  • 15. The outcome of matched unrelated donor bone marrow transplantation in patients with hematologic malignancies using molecular typing for donor selection and graft-versus-host disease prophylaxis regimen of cyclosporine, methotrexate, and prednisone.
    Nademanee A, Schmidt GM, Parker P, Dagis AC, Stein A, Snyder DS, O'Donnell M, Smith EP, Stepan DE, Molina A.
    Blood; 1995 Aug 01; 86(3):1228-34. PubMed ID: 7620176
    [Abstract] [Full Text] [Related]

  • 16. Superior survival associated with transplantation of matched unrelated versus one-antigen-mismatched unrelated or highly human leukocyte antigen-disparate haploidentical family donor marrow grafts for the treatment of hematologic malignancies: establishing a treatment algorithm for recipients of alternative donor grafts.
    Drobyski WR, Klein J, Flomenberg N, Pietryga D, Vesole DH, Margolis DA, Keever-Taylor CA.
    Blood; 2002 Feb 01; 99(3):806-14. PubMed ID: 11806980
    [Abstract] [Full Text] [Related]

  • 17. Graft-versus-host disease prevention in allogeneic bone marrow transplantation from histocompatible siblings. A pilot study using immunotoxins for T cell depletion of donor bone marrow.
    Filipovich AH, Vallera DA, Youle RJ, Haake R, Blazar BR, Arthur D, Neville DM, Ramsay NK, McGlave P, Kersey JH.
    Transplantation; 1987 Jul 01; 44(1):62-9. PubMed ID: 3299923
    [Abstract] [Full Text] [Related]

  • 18. Intentional induction of mixed chimerism and achievement of antitumor responses after nonmyeloablative conditioning therapy and HLA-matched donor bone marrow transplantation for refractory hematologic malignancies.
    Spitzer TR, McAfee S, Sackstein R, Colby C, Toh HC, Multani P, Saidman S, Weyouth DW, Preffer F, Poliquin C, Foley A, Cox B, Andrews D, Sachs DH, Sykes M.
    Biol Blood Marrow Transplant; 2000 Jul 01; 6(3A):309-20. PubMed ID: 10905768
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Unrelated donor BMT for Wiskott-Aldrich syndrome.
    Lenarsky C, Weinberg K, Kohn DB, Parkman R.
    Bone Marrow Transplant; 1993 Aug 01; 12(2):145-7. PubMed ID: 8401361
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.